

Figure 1




All Coronavirus-infected		Coronavirus as Sole Pathogen	
	NTZ	**Placebo**	**NTZ**	**Placebo**
N (censored)	51 (6)	41 (6)	35 (4)	28 (4)
Median (IQR)	176.3 (104-248)	241.6 (152-395)	155.2 (101-245)	200.6 (131-452)
P-value, Wilcoxon	0.0469		0.0893	

Figure 2




All Coronavirus-infected			Coronavirus as Sole Pathogen	
	NTZ	Placebo	NTZ	Placebo
N (censored)	49 (4)	39 (4)	33 (1)	26 (4)
Median (IQR)	147.3 (107-264)	208.2 (152-300)	147.3 (103-224)	220.6 (152-294)
P-value, Wilcoxon	0.0342		0.0351	

Figure 3



	NTZ	Placebo
N (censored)	48 (12)	32 (6)
Median (IQR)	105.7 (59-366)	215.6 (117-416)
Magnitude of benefit	110 (58, 50)	
P-value, Wilcoxon	0.1827	
P-value, Log Rank	0.5510	

Figure 4



[1] For this purpose, respiratory domains include chest, cough, nose, throat and head.

Figure 5



Concept
Domain
Subdomain
Items
Viral Respiratory Illness
Body
Head
Eyes
Throat
Gastrointestinal
Nose
Chest
Cough
1. Body aches or pains
2. Chills or shivering
3. Feel cold
4. Feel sticky
5. Feel hot
6. Sweating
7. Lack of appetite
8. Sleeping
9. Feel weak or tired
1. Headache
2. Head congestion
1. Sore or painful eyes
2. Teary or watery eyes
3. Eyes sensitive to light
1. Difficulty swallowing
2. Sore or painful throat
3. Scratchy or itchy throat
1. Diarrhea
2. Feel nauseous
3. Stomach ache
4. Vomit
1. Stuffy/congested nose
2. Runny or pouring nose
3. Sinus pressure
4. Sneezing
1. Trouble breathing
2. Chest tightness
3. Chest congestion
1. Coughing
2. Dry or hacking cough
3. Coughed up mucus or phlegm
4. Wet or loose cough

Figure 6




Screened
Randomized
Safety Population
mITT Population
1,390 screened
298 failed inclusion/exclusion criteria
1,092 randomized
156 positive for EV/RV allocated to ongoing EV/RV study
1 withdrew consent prior to dosing
472 received at least one dose of NTZ study medication
288 negative for SARS-CoV-2
184 NTZ-treated subjects with laboratory-confirmed SARS-CoV-2 infection
463 received at least one dose of placebo study medication
268 negative for SARS-CoV-2
195 placebo-treated subjects with laboratory-confirmed SARS-CoV-2 infection

Figure 7


A.
Time to Sustained Response
Proportion Not Responded
Time to Sustained Response (days)
NTZ
Placebo
B.
Time to Return to Usual Health
Proportion Not Returned
Time to Return to Usual Health (days)
NTZ
Placebo